Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US
Current Medical Research and Opinion, 06/25/09
Charles MS et al. - Under a range of assumptions and study limitations around cohorts, clinical effects, and treatment patterns, this long-term analysis showed that pioglitazone plus metformin, when compared to rosiglitazone plus metformin, was a dominant treatment strategy within the US payer setting. Results were driven by the combination of modest differences in QALYs and modest savings in total complication costs over 35 years.
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
A Clinical Review of Echinocandins in Pediatric Patients
Annals of Pharmacotherapy, 12/16/09
Use of psychotropic drugs and analgesics among users of antiobesity drugs - a population based study
Pharmacoepidemiology and Drug Safety, 12/16/09
Measuring exacerbations in obstructive lung disease
Pharmacoepidemiology and Drug Safety, 12/16/09
Today in Pharmacoeconomics...keeping you current
Receive free subspecialty "5-minute updates" via email
Costs of hospital-based methadone maintenance treatment in HIV/AIDS control among injecting drug users in Indonesia
Health Policy, 12/16/09
Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
Cost Effectiveness and Resource Allocation, 12/15/09
Cost-effectiveness of single agent, uptitration and switching statin treatment strategies for lipid lowering in Sweden
Current Medical Research and Opinion, 12/14/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


